Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 6, 2009 - Issue 7
Submit an article Journal homepage
572
Views
63
CrossRef citations to date
0
Altmetric
Reviews

Controlled delivery of antisense oligonucleotides: a brief review of current strategies

Xiubo Zhao University of Manchester, School of Physics and Astronomy, Biological Physics Group, Schuster Building, Manchester M13 9PL, UK +44 161 306 3926; [email protected]
,
Fang Pan University of Manchester, School of Physics and Astronomy, Biological Physics Group, Schuster Building, Manchester M13 9PL, UK +44 161 306 3926; [email protected]
,
Cathy M Holt Core Technology Facility University of Manchester, School of Medicine, Cardiovascular Research Group, Oxford Road, Manchester M13 9NT, UK
,
Andrew L Lewis Biocompatibles UK Ltd, Farnham, Surrey GU9 8QL, UK
&
Jian R Lu University of Manchester, School of Physics and Astronomy, Biological Physics Group, Schuster Building, Manchester M13 9PL, UK +44 161 306 3926; [email protected]
Pages 673-686 | Published online: 25 Jun 2009

Bibliography

  • Crooke ST. Progress in antisense technology. Annu Rev Med 2004;55:61-95
  • Sepp-Lorenzino L, Ruddy M. Challenges and opportunities for local and systemic delivery of siRNA and antisense oligonucleotides. Clin Pharmacol Ther 2008;84:628-32
  • Aboul-Fadl T. Antisense oligonucleotide technologies in drug discovery. Expert Opin Drug Discov 2006;1:285-8
  • Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978;75:280-4
  • Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 1978;75:285-8
  • Toub N, Malvy C, Fattal E, Couvreur P. Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. Biomed Pharmacother 2006;60:607-20
  • Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 2002;1:347-55
  • Hughes MD, Hussain M, Nawaz Q, et al. The cellular delivery of antisense oligonucleotides and ribozymes. Drug Discov Today 2001;6:303-15
  • Isaka Y, Imai E, Takahara S, Rakugi H. Oligonucleotidic therapeutics. Expert Opin Drug Discov 2008;3:991-6
  • Sundaram S, Viriyayuthakorn S, Roth CM. Oligonucleotide structure influences the interactions between cationic polymers and oligonucleotides. Biomacromolecules 2005;6:2961-8
  • Eckstein F. The versatility of oligonucleotides as potential therapeutics. Expert Opin Biol Ther 2007;7:1021-34
  • Walder RY, Walder JA. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci USA 1988;85:5011-5
  • Read ML, Bremner KH. Antisense strategies and non-viral gene therapy for cancer. Expert Opin Ther Patents 2002;12:379-91
  • De-Rosa G, Quaglia F, Bochot A, et al. Long-term release and improved intracellular penetration of oligonucleotide-polyethylenimine complexes entrapped in biodegradable microspheres. Biomacromolecules 2003;4:529-36
  • Lee LK, Williams CL, Devore D, Roth CM. Poly(propylacrylic acid) enhances cationic lipid-mediated delivery of antisense oligonucleotides. Biomacromolecules 2006;7:1502-8
  • Malik R, Roy L. Design and development of antisense drugs. Expert Opin Drug Discov 2008;3:1189-207
  • Wang L, Kristensen J, Ruffner DE. Delivery of antisense oligonucleotides using HPMA polymer: synthesis of a thiol polymer and its conjugation to water-soluble molecules. Bioconjug Chem 1998;9:749-57
  • Leaman DW. Recent progress in oligonucleotide therapeutics: antisense to aptamers. Expert Opin Drug Discov 2008;3:997-1009
  • Opalinska J. Nucleic acid drugs in the clinic. Expert Opin Drug Discov 2007;2:321-33
  • Vasir JK, Labhasetwar V. Polymeric nanoparticles for gene delivery. Expert Opin Drug Deliv 2006;3:325-44
  • Segura T, Shea LD. Materials for non-viral gene delivery. Annu Rev Mater Res 2001;31:25-46
  • Good L. Antisense antibacterials. Expert Opin Ther Patents 2002;12:1173-9
  • El-Aneed A. An overview of current delivery systems in cancer gene therapy. J Control Release 2004;94:1-14
  • Karinaga R, Anada T, Minari J, et al. Galactose-PEG dual conjugation of b-(1-3)-D-glucan schizophyllan for antisense oligonucleotides delivery to enhance the cellular uptake. Biomaterials 2006;27:1626-35
  • Zuhorn IS, Engberts JBFN, Hoekstra D. Gene delivery by cationic lipid vectors: overcoming cellular barriers. Eur Biophys J 2007;36:349-62
  • Chirila TV, Rakoczy PE, Garrett KL, et al. The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides. Biomaterials 2002;23:321-42
  • Goyal P, Goyal K, Kumar SGV, et al. Liposomal drug delivery systems – clinical applications. Acta Pharm 2005;55:1-25
  • Christian DA, Cai S, Bowen DM, et al. Polymersome carriers: from self-assembly to siRNA and protein therapeutics. Eur J Pharm Biopharm 2009;71:463-74
  • Garcia-Chaumont C, Seksek O, Grzybowska J, et al. Delivery systems for antisense oligonucleotides. Pharmacol Ther 2000;87:255-77
  • Abes S, Williams D, Prevot P, et al. Endosome trapping limits the efficiency of splicing correction by PNA-oligolysine conjugates. J Control Release 2006;2006:595-604
  • Horwich MD, Zamore PD. Design and delivery of antisense oligonucleotides to block microRNA function in cultured Drosophila and human cells. Nat Protocols 2008;3:1537-49
  • Rayburn ER, Wang H, Zhang R. Antisense-based cancer therapeutics: are we there yet? Expert Opin Emerg Drugs 2006;11:337-52
  • Chiarantini L, Ceras A, Fraternale A, et al. Comparison of novel delivery systems for antisense peptide nucleic acids. J Control Release 2005;109:24-36
  • Juliano R, Alam MR, Dixit V, Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 2008;36:4158-71
  • Shi F, Hoekstra D. Effective intracellular delivery of oligonucleotides in order to make sense of antisense. J Control Release 2004;97:189-209
  • Godfray J, Estibeiro P. The potential of antisense as a CNS therapeutic. Expert Opin Ther Targets 2003;7:363-76
  • Veldhoen S, Laufer SD, Restle T. Recent developments in peptide-based nucleic acid delivery. Int J Mol Sci 2008;9:1276-320
  • Deshayes S, Morris MC, Divita G, Heitz F. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. CMLS Cell Mol Life Sci 2005;62:1839-49
  • Maier MA, Esau CC, Siwkowski AM, et al. Evaluation of basic amphipathic peptides for cellular delivery of antisense peptide nucleic acids. J Med Chem 2006;49:2534-42
  • Bayele HK, Sakthivel T, O'Donell M, et al. Versatile peptide dendrimers for nucleic acid delivery. J Pharm Sci 2005;94:446-57
  • Martin VL, Roy S, Armitage BA. Recent advances in the development of peptide nucleic acid as gene-targeted drug. Expert Opin Biol Ther 2004;4:337-48
  • Kichler A. Gene transfer with modified polyethylenimines. J Gene Med 2004;6:S3-10
  • Jia N, Lian Q, Shen H, et al. Intracellular delivery of quantum dots tagged antisense oligodeoxynucleotides by functionalized multiwalled carbon nanotubes. Nano Lett 2007;7:2976-80
  • Gao S, Chen J, Dong L, et al. Targeting delivery of oligonucleotide and plasmid DNA to hepatocyte via galactosylated chitosan vector. Eur J Pharm Biopharm 2005;60:327-34
  • Hadaschik BA, Jackson J, Fazli L, et al. Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer. BJU Int 2008;102:610-6
  • Mehier-Humbert S, Guy RH. Physical methods for gene transfer: improving the kinetics of gene delivery into cells. Adv Drug Deliv Rev 2005;57:733-53
  • Zhao X, Pan F, Zhang Z, et al. Nanostructure of polyplexes formed between cationic diblock copolymer and antisense oligodeoxynucleotide and its influence on cell transfection efficiency. Biomacromolecules 2007;8:3493-502
  • Felgner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987;84:7413-7
  • Zhang S, Xu Y, Wang B, et al. Cationic compounds used in lipoplexes and polyplexes for gene delivery. J Control Release 2004;100:165-80
  • Rao NM, Gopal V. Cationic lipids for gene delivery in vitro and in vivo. Expert Opin Ther Patents 2006;16:825-44
  • Lindner LH, Brock R, Arndt-Jovin D, Eibl H. Structural variation of cationic lipids: Minimum requirement for improved oligonucleotide delivery into cells. J Control Release 2006;110:444-56
  • Farhood H, Serbina S, Huang L. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim Biophys Acta 1995;1235:289-95
  • Yamauchi M, Kusano H, Saito E, et al. Improved formulations of antisense oligodeoxynucleotides using wrapped liposomes. J Control Release 2006;114:268-75
  • Pakunlu RI, Wang Y, Saad M, et al. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J Control Release 2006;114:153-62
  • Wong FMP, Macadam SA, Kim A, et al. A lipid-based delivery system for antisense oligonucleotides derived from a hydrophobic complex. J Drug Target 2002;10:615-23
  • Wilson A, Zhou W, Champion HC, et al. Targeted delivery of oligodeoxynucleotides to mouse lung endothelial cells in vitro and in vivo. Mol Ther 2005;12:510-8
  • Chiu S-J, Liu S, Perrotti D, et al. Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. J Control Release 2006;112:199-207
  • Zhang Y, Qi XR, Gao Y, et al. Mechanisms of co-modified liver-targeting liposomes as gene delivery carriers based on cellular uptake and antigens inhibition effect. J Control Release 2007;117:281-90
  • Lv H, Zhang S, Wang B, et al. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 2006;114:100-9
  • Weyermann J, Lochmann D, Zimmer A. Comparison of antisense oligonucleotide drug delivery systems. J Control Release 2004;100:411-23
  • Zhao X, Zhang Z, Pan F, et al. Plasmid DNA complexation with phosphorylcholine diblock copolymers and its effect on cell transfection. Langmuir 2008;24:6881-8
  • Merdan T, Kopecek J, Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev 2002;54:715-58
  • Neu M, Fischer D, Kissel T. Recent advances in rational gene transfer vector design based on poly(ethylene imine) and its derivatives. J Gene Med 2005;7:992-1009
  • Pack DW, Hoffman AS, Pun S, Stayton PS. Design and developement of polymers for gene delivery. Nat Rev Drug Discov 2005;4:581-93
  • Godbey WT, Wu KK, Mikos AG. Poly(ethylenimine) and its role in gene delivery. J Control Release 1999;60:149-60
  • Dufès C, Uchegbu IF, Schätzlein AG. Dendrimers in gene delivery. Adv Drug Deliv Rev 2005;57:2177-202
  • Nam HY, Hahn HJ, Nam K, et al. Evaluation of generations 2, 3 and 4 arginine modified PAMAM dendrimers for gene delivery. Int J Pharm 2008;363:199-205
  • Zhao XB, Lee RJ. Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor. Adv Drug Deliv Rev 2004;56:1193-204
  • Sarkar T, Conwell CC, Harvey LC, et al. Condensation of oligonucleotides assembled into nicked and gapped duplexes: potential structures for oligonucleotide delivery. Nucleic Acids Res 2005;33:143-51
  • Zhu J, Tang A, Law LP, et al. Amphiphilic core-shell nanoparticles with poly(ethylenimine) shells as potential gene delivery carriers. Bioconjug Chem 2005;16:139-46
  • Carlisle RC, Etrych T, Briggs SS, et al. Polymer-coated polyethylenimine/DNA complexes designed for triggered activation by intracellular reduction. J Gene Med 2004;6:337-44
  • Dailey LA, Kleemann E, Merdan T, et al. Modified polyethylenimines as non viral gene delivery systems for aerosol therapy: effects of nebulization on cellular uptake and transfection efficiency. J Control Release 2004;100:425-36
  • Williams JH, Schray RC, Sirsi SR, Lutz GJ. Nanopolymers improve delivery of exon skipping oligonucleotides and concomitant dystrophin expression in skeletal muscle of mdx mice. BMC Biotechnol 2008;8:35
  • Sirsi SR, Williams JH, Lutz GJ. Poly(ethylene imine)–poly(ethylene glycol) copolymers facilitate efficient delivery of antisense oligonucleotides to nuclei of mature muscle cells of mdx mice. Hum Gene Ther 2005;16:1307-17
  • Kim SH, Mok H, Jeong JH, et al. Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate. Bioconjug Chem 2006;17:241-4
  • Vinogradov SV, Batrakova EV, Li S, Kabanov AV. Mixed polymer micelles of amphiphilic and cationic copolymers for delivery of antisense oligonucleotides. J Drug Target 2004;12:517-26
  • Glodde M, Sirsi SR, Lutz GJ. Physiochemical properties of low and high molecular weight poly(ethylene glycol)-grafted poly(ethylene imine) copolymers and their complexes with oligonucleotides. Biomacromolecules 2006;7:347-56
  • Lomas H, Marzia Massignani, Abdullah KA, et al. Non-cytotoxic polymer vesicles for rapid and efficient intracellular delivery. Faraday Discuss 2008;139:143-59
  • Lomas H, Canton I, MacNeil S, et al. Biomimetic pH sensitive polymersomes for efficient DNA encapsulation and delivery. Adv Mater 2007;19:4238-43
  • Nafee N, Taetz S, Schneider M, et al. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine 2007;3:173-83
  • Pan B, Cui D, Sheng Y, et al. Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system. Cancer Res 2007;67:8156-63
  • Wernig K, Griesbacher M, Andreae F, et al. Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles. J Control Release 2008;130:192-8
  • Tahara K, Sakai T, Yamamoto H, et al. Establishing chitosan coated PLGA nanosphere platform loaded with wide variety of nucleic acid by complexation with cationic compound for gene delivery. Int J Pharm 2008;354:210-6
  • Giljohann DA, Seferos DS, Patel PC, et al. Oligonucleotide loading determines cellular uptake of DNA-modified gold nanoparticles. Nano Lett 2007;7:3818-21
  • Rosi NL, Giljohann DA, Thaxton CS, et al. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 2006;312:1027-30
  • Patel PC, Giljohann DA, Seferos DS, Mirkin CA. Peptide antisense nanoparticles. Proc Natl Acad Sci USA 2008;105:17222-6
  • Zhu S-G, Xiang J-J, Li X-L, et al. Poly(L-lysine)-modified silica nanoparticles for the delivery of antisense oligonucleotides. Biotechnol Appl Biochem 2004;39:179-87
  • Wartlick H, Spänkuch-Schmitt B, Strebhardt K, et al. Tumour cell delivery of antisense oligonucleotides by human serum albumin nanoparticles. J Control Release 2004;96:483-95
  • Steinhauser IM, Langer K, Strebhardt KM, Spänkuch B. Effect of trastuzumab modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation. Biomaterials 2008;29:4022-8
  • Santos ALGD, Bochot A, Doyle A, et al. Sustained release of nanosized complexes of polyethylenimine and anti-TGF-β2 oligonucleotide improves the outcome of glaucoma surgery. J Control Release 2006;112:369-81
  • Kovacs JR, Zheng Y, Shen H, Meng WS. Polymeric microspheres as stabilizing anchors for oligonucleotide delivery to dendritic cells. Biomaterials 2005;26:6754-61
  • Akhtar S, Lewis KJ. Antisense oligonucleotide delivery to cultured macrophages is improved by incorporation into sustained-release biodegradable polymer microspheres. Int J Pharm 1997;151:57-67
  • Phull H, Lien Y-HH, Salkini MW, et al. Delivery of intercellular adhesion molecule-1 antisense oligonucleotides using a topical hydrogel tissue sealant in a murine partial nephrectomy/ischemia model. Urology 2008;72:690-5
  • Vinogradov SV, Batrakova EV, Kabanov AV. Nanogels for oligonucleotide delivery to the brain. Bioconjug Chem 2004;15:50-60
  • Khan A, Sommer W, Fuxe K, Akhtar S. Site-specific administration of antisense oligonucleotides using biodegradable polymer microspheres provides sustained delivery and improved subcellular biodistribution in the neostriatum of the rat brain. J Drug Target 2000;8:319-34
  • Nyce JW. Antisense oligonucleotides: local delivery enhances their therapeutic potential. Expert Opin Ther Patents 1999;9:263-7
  • Takahashi H, Letourneur D, Grainger DW. Delivery of large biopharmaceuticals from cardiovascular stents: a review. Biomacromolecules 2007;8:3281-93
  • Zhang Z, Cao X, Zhao X, et al. Controlled delivery of antisense oligodeoxynucleotide from cationically modified phosphorylcholine polymer films. Biomacromolecules 2006;7:784-91
  • Zhang Z, Cao X, Zhao X, et al. Controlled delivery of anti-sense oligodeoxynucleotide from multilayered biocompatible phosphorylcholine polymer films. J Control Release 2008;130:69-76
  • Lewis AL. Phosphorylcholine-based polymers and their use in the prevention of biofouling. Colloids Surf B Biointerfaces 2000;18:261-75
  • Lewis AL, Freeman RNT, Redman RP, et al. Wettable phosphorylcholine-containing polymers useful in blood filtration. J Mater Sci Mater Med 2003;14:39-45
  • Lewis AL, Hughes PD, Kirkwood LC, et al. Synthesis and characterisation of phosphorylcholine-based polymers useful for coating blood filtration devices. Biomaterials 2000;21:1847-59
  • Lewis AL, Tolhurst LA, Stratford PW. Analysis of a phosphorylcholine-based polymer coating on a coronary stent pre- and post-implantation. Biomaterials 2002;23:1697-706
  • Willis SL, Court JL, Redman RP, et al. A novel phosphorylcholine-coated contact lens for extended wear use. Biomaterials 2001;22:3261-72
  • Rose SF, Lewis AL, Hanlon GW, Lloyd AW. Biological responses to cationically charged phosphorylcholine-based materials in vitro. Biomaterials 2004;25:5125-35
  • Zhao X, Pan F, Coffey P, Lu JR. Cationic copolymer-mediated DNA immobilization: interfacial structure and composition as determined by ellipsometry, dual polarization interferometry, and neutron reflection. Langmuir 2008;24:13556-64
  • Zhao X, Zhang Z, Pan F, et al. Solution pH regulated interfacial adsorption of diblock phosphorylcholine copolymers. Langmuir 2005;21:9597-603
  • Zhao X, Zhang Z, Pan F, et al. DNA immobilization using biocompatible diblock phosphorylcholine copolymers. Surf Interface Anal 2006;38:548-51
  • Chim YTA, Lam JKW, Ma Y, et al. Structural study of DNA condensation induced by novel phosphorylcholine-based copolymers for gene delivery and relevance to DNA protection. Langmuir 2005;21:3591-8
  • Lam JKW, Ma Y, Armes SP, et al. Phosphorylcholine–polycation diblock copolymers as synthetic vectors for gene delivery. J Control Release 2004;100:293-312
  • Salvage JP, Rose SF, Phillips GJ, et al. Novel biocompatible phosphorylcholine-based self-assembled nanoparticles for drug delivery. J Control Release 2005;104:259-70
  • Palmer RR, Lewis AL, Kirkwood LC, et al. Biological evaluation and drug delivery application of cationically modified phospholipid polymers. Biomaterials 2004;25:4785-96
  • Xu J-P, Ji J, Chen W-D, Shen J-C. Novel biomimetic polymersomes as polymer therapeutics for drug delivery. J Control Release 2005;107:502-12
  • Giacomelli C, Men LL, Borsali R, et al. Phosphorylcholine-based pH-responsive diblock copolymer micelles as drug delivery vehicles: light scattering, electron microscopy, and fluorescence experiments. Biomacromolecules 2006;7:817-28
  • Lewis AL, Vick TA, Collias ACM, et al. phosphorylcholine-based polymer coatings for stent drug delivery. J Mater Sci Mater Med 2001;12:865-70
  • Lewis AL, Furze JD, Small S, et al. Long-term stability of a coronary stent coating post-implantation. J Biomed Mater Res (Appl Biomater) 2002;63:699-705
  • Zhao X, Pan F, Lu JR. Interfacial immobilization of DNA molecules. Annu Rep Prog Chem Sect C Phys Chem 2007;103:261-86
  • Chan KH, Armstrong J, Withers S, et al. Vascular delivery of c-myc antisense from cationically modified phosphorylcholine coated stents. Biomaterials 2007;28:1218-24
  • Lewis A, Berwick J, Davies MC, et al. Synthesis and characterisation of cationically modified phospholipid polymers. Biomaterials 2004;25:3099-108
  • Branco MC, Schneider JP. Self-assembling materials for therapeutic delivery. Acta Biomaterialia 2009;5:817-31
  • Nagai Y, Unsworth LD, Koutsopoulos S, Zhang S. Slow release of molecules in self-assembling peptide nanofiber scaffold. J Control Release 2006;115:18-25

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.